Chris Harbron
Roche (United Kingdom)(GB)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Computational Drug Discovery Methods, Protein Degradation and Inhibitors, Gene expression and cancer classification, Synthesis and biological activity
Most-Cited Works
- → Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis(2007)365 cited
- → Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples(2015)325 cited
- → Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)(2010)261 cited
- → RefPlus: an R package extending the RMA Algorithm(2007)87 cited
- → The use of external controls: To what extent can it currently be recommended?(2021)86 cited
- → Synergistic Effects of p38 Mitogen-Activated Protein Kinase Inhibition with a Corticosteroid in Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease(2011)85 cited
- → Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System(2014)75 cited
- → In search of preclinical robustness(2012)68 cited
- → Synthetic data use: exploring use cases to optimise data utility(2021)68 cited
- → Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data(2022)66 cited